Gesynta Pharma

Gesynta Pharma is a Swedish pharmaceutical company developing unique drug candidates aimed at reducing harmful inflammation and increasing blood flow in the human microvasculature, thereby providing safe and effective treatments for several serious diseases. The main drug product, GS-248, is about to enter Phase II clinical trials. GS-248 is an oral small-molecule drug used to treat microvascular disorders under conditions of chronic inflammation.